Abstract
Objectives. To determine the timing and predictors of T2-lesion resolution in myelin-oligodendrocyte-glycoprotein-antibody-associated disease (MOGAD).
Methods. This retrospective observational study using standard of care data had inclusion criteria of: MOGAD diagnosis, >2 MRI’s 12 months apart, and >1 brain/spinal cord T2-lesion. The median (interquartile-range[IQR]) number of MRI’s (82% at disease onset) per-patient were: brain, 5(2-8); spine, 4(2-8). Predictors of T2-lesion resolution were assessed with age- and sex-adjusted generalized estimating equations and stratified by T2-lesion size (small <1 cm; large ≥1 cm).
Results. We studied 583 T2-lesions (brain, 512[88%]; spinal cord, 71[12%]) from 55 patients. At last MRI (median follow-up 54 months[IQR, 7-74]), 455 T2-lesions (78%) resolved. The median (IQR) time to resolution was 3 months (1.4-7.0). Small T2-lesions resolved more frequently and faster than large T2-lesions. Acute T1-hypointesity decreased the likelihood (odds ratio[95% confidence interval]) of T2-lesion resolution independent of size (small: 0.23[0.09, 0.60], p=0.002; large: 0.30[0.16, 0.55], p<0.001) while acute steroids favored resolution of large T2-lesions (1.75[1.01, 3.03], p=0.046). Notably, 32/55 (58%) T2-lesions resolved without treatment.
Discussion. The high frequency of spontaneous T2-lesion resolution suggests this represents MOGAD’s natural history. The speed of T2-lesion resolution and influence of size, corticosteroids and T1-hypointensity on this phenomenon gives insight into MOGAD pathogenesis.
- Received November 29, 2022.
- Accepted in final form April 17, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
